Mozart Therapeutics racks up $55m Series A

Mozart Therapeutics Inc, a biopharmaceutical company focused on treating autoimmune and inflammatory disease, has raised $55 million in Series A financing.

ByIris Dorbian

27 October 2021•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Mozart Therapeutics racks up $55m Series A

Alexandria Venture Investments

Altitude Life Science Ventures

ARCH Venture Partners

Related articles